{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019158", "CSN": null, "TRF": "ORD_1308443_01", "MRN": "47918183", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1046731", "clinicalId": "1048102", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1308443_01", "SampleName": "US1258356.01", "Version": "0", "Sample": {"FM_Id": "ORD_1308443_01", "SampleId": "US1258356.01", "BlockId": "S111-05667A", "TRFNumber": "ORD_1308443_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_02_23", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98564", "MRN": "47918183", "FullName": "\u5433\u9326\u79c0", "FirstName": "Chin_Hsiu", "LastName": "Wu", "SubmittedDiagnosis": "Invasive adenocarcinoma, Urinary bladder", "Gender": "Male", "DOB": "1948_11_01", "OrderingMD": "\u9b4f\u5b50\u921e", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Bladder", "CollDate": "2022_02_14", "ReceivedDate": "2022-03-04 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Bladder Carcinoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "FGFR2"}, {"Gene": "FGFR3"}]}, "Summaries": {"alterationCount": "12", "clinicalTrialCount": "11", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "IDH2", "isVUS": "true", "variantName": "M397V"}, {"geneName": "MLH1", "isVUS": "true", "variantName": "V612I"}, {"geneName": "PARP3", "isVUS": "true", "variantName": "A235V,H146Y"}, {"geneName": "SMO", "isVUS": "true", "variantName": "R199W"}, {"geneName": "ZNF703", "isVUS": "true", "variantName": "L63H"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). In numerous cancer type_specific studies as well as a large_scale pan_cancer analysis, KRAS amplification was shown to correlate with increased expression (McIntyre et al., 2005; 16354586, Mita et al., 2009; 19545448, Birkeland et al., 2012; 23099803, Chen et al., 2014; 24874471). Additionally, KRAS amplification correlated with sensitivity of cancer cell lines to KRAS knockdown, suggesting that amplified KRAS is an oncogenic driver (Chen et al., 2014; 24874471). KRAS amplification has been reported in 1_4% of bladder urothelial carcinomas (cBio_Kim et al., 2014; 25092538, cBio_Robertson et al., 2017; 28988769). Prognostic implications of KRAS amplification in the context of urothelial carcinoma have not been extensively investigated in the literature (PubMed, Nov 2021). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Clinical evidence that KRAS amplification in the absence of a concurrent KRAS activating mutation is sensitive to MEK inhibitors is limited. A Phase 2 study of selumetinib plus docetaxel in patients with gastric cancer reported 1/2 patients with KRAS amplification experienced a PR (Lee et al., 2018; ASCO Abstract 4061). A patient with cervical cancer harboring both KRAS and PIK3CA amplification treated with the combination of trametinib and the AKT inhibitor GSK2141795 achieved a SD (Lui et al., 2019; 31118140).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT02407509", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}, {"nctId": "NCT03162627", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MDM2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic (Brown et al., 2009; 19935675, Cordon_Cardo et al., 1994; 8306343). Overexpression or amplification of MDM2 is frequent in cancer (Beroukhim et al., 2010; 20164920). Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time_to_treatment failure on anti_PD_1/PD_L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification (Kato et al., 2017; 28351930) and 2/3 patients with MDM2 or MDM4 amplification (Singavi et al., 2017; ESMO Abstract 1140PD) experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression_free survival (PFS) in a retrospective analysis of non_small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)(Rizvi et al., 2018; 29337640). The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification (Rizvi et al., 2018; 29337640). MDM2 amplification has been reported in 5_9% of urothelial carcinoma cases (Maluf et al., 2006; 16984978, Montie, 2005; 16006876, Tuna et al., 2003; 12908522, Veerakumarasivam et al., 2008; 18451213, Simon et al., 2002; 11971182, L\u00f3pez_Knowles et al., 2006; 17062677, The Cancer Genome Atlas Research Network., 2014; 24476821). Altered MDM2 protein expression in invasive urothelial carcinoma has been reported in several studies, with the reported frequency ranging from 9_61% (Jahnson and Karlsson, 2000; 10931462, Lianes et al., 1994; 8064890, Maluf et al., 2006; 16984978, Ow et al., 2000; 10767717, Schmitz_Dr\u00e4ger et al., 1997; 9412812). One study reported that alteration of MDM2 or TP53 was not associated with outcomes of patients with bladder cancer (L\u00f3pez_Knowles et al., 2006; 17062677). Studies on correlation between MDM2 expression and disease stage of urothelial cancer have yielded conflicting results; MDM2 expression alone does not appear to be a marker of clinical outcome in patients with urothelial carcinoma (Lianes et al., 1994; 8064890, Jahnson and Karlsson, 2000; 10931462, Maluf et al., 2006; 16984978). MDM2 antagonists disrupt the MDM2_p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2_p53 antagonist alrizomadlin (APG_115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%\u201338% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non_small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti_leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN_6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T_cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric_Bernstam et al., 2017; ASCO Abstract 2505).", "Include": "true", "ClinicalTrialNote": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03449381", "Include": "true"}, {"nctId": "NCT03611868", "Include": "true"}, {"nctId": "NCT03725436", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). In the Bladder Urothelial Carcinoma TCGA dataset, concurrent homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of cases, and CDKN2A mutation has been found in 5.5% of cases (The Cancer Genome Atlas Research Network., 2014; 24476821). Loss of CDKN2A/B or loss of p14ARF, p16INK4a, or p15INK4b protein expression occurs frequently in bladder urothelial carcinoma, with reports of frequency ranging from 18% to 77% (Lee et al., 2010; 20890425, Bartoletti et al., 2007; 17612565, Eissa et al., 2004; 15590562, Korkolopoulou et al., 2001; 11223676, Le et al., 2001; 11720438, Ross et al., 2014; 23887298, Yurakh et al., 2006; 16624482, Le et al., 2004; 15257544, Orlow et al., 1995; 7563186). Several studies have associated loss of CDKN2A/B or loss of p16INK4a and p15INK4b expression with disease progression, decreased recurrence_free disease, and poor prognosis in patients with urothelial carcinoma, although results have been inconsistent (Kim et al., 2014; 25092538, Pollard et al., 2010; 20334706, Lee et al., 2010; 20890425, Yin et al., 2008; 18234280, Bartoletti et al., 2007; 17612565, Rebouissou et al., 2012; 22422578, Yurakh et al., 2006; 16624482, Korkolopoulou et al., 2001; 11223676). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KDM6A", "Include": "true", "Alterations": {"Alteration": {"Name": "L1119del", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "L1119del"}}, "Interpretation": "KDM6A encodes a histone H3 lysine 27 demethylase UTX, which functions as a transcriptional regulator (van Haaften et al., 2009; 19330029). A significant number of inactivating KDM6A mutations have been found across multiple tumor types, suggesting a role as a tumor suppressor (van Haaften et al., 2009; 19330029). KDM6A mutations have been reported in 3.9% of samples analyzed, with the highest incidence in tumors of the urinary tract (31%), liver (7.3%), endometrium (6.7%), salivary gland (6.0%), and pancreas (5.1%) (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). KDM6A mutations or copy number alterations have also been identified in medulloblastoma (8.9%)(Robinson et al., 2012; 22722829), adenoid cystic carcinoma (6.7%) (Ho et al., 2013; 23685749), and metastatic prostate cancer (10%) (Grasso et al., 2012; 22722839). KDM6A inactivation has been found as a recurrent tumorigenic event in male T_cell acute lymphoblastic leukemia (T_ALL), and loss of KDM6A increased the sensitivity of T_ALL cells to therapies targeting histone H3 lysine 27 methylation in preclinical assays (Van der Meulen et al., 2014; 25320243). However, KDM6A overexpression has been noted in breast cancer and renal cell carcinoma, and correlated with inferior prognosis in patients with breast cancer (Wang et al., 2013; 23792809, Kim et al., 2014; 24491801, Shen et al., 2012; 23057811). There are no therapies available to address KDM6A alterations in cancer.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 26_49% of urothelial carcinomas (Mylona et al., 2008; 18254781, Amira et al., 2003; 14501713); MSI_H has also been reported in multiple case studies of upper urinary tract urothelial carcinoma (Bai et al., 2013; 23690119). MSI, as determined through loss of MSH2 or MSH6 protein expression, correlated with non_invasive, well_differentiated bladder tumors and favorable overall survival (Mylona et al., 2008; 18254781). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels in urothelial carcinoma (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003, Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Miao et al., 2018; 30150660, Samstein et al., 2019; 30643254, Sarid et al., 2019; ESMO Abstract 938, Marabelle et al., 2020; 32919526). In the Bladder Urothelial Carcinoma TCGA dataset, the median somatic mutation burden was 5.5 mutations per megabase (muts/Mb)(Cancer Genome Atlas Research Network, 2014; 24476821). One study reported that the number of somatic mutations positively correlates with increased tumor stage and grade of bladder cancers (Cazier et al., 2016; 24777035). For patients with metastatic urothelial carcinoma receiving atezolizumab, however, higher median mutation load has been reported to be significantly associated with improved PFS and OS (Rosenberg et al., 2016; ASCO Abstract 104)(Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in urothelial carcinoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_L1 (Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660) and anti_PD_1 immunotherapeutic agents (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003). For patients with metastatic urothelial carcinoma treated with the PD_L1 inhibitor atezolizumab, those with a significantly increased mutational load (9.7 Muts/Mb or greater by this assay or others) were associated with response and longer OS compared with those with lower TMB (Rosenberg et al., 2016; 26952546, Powles et al., 2018; 29268948, Balar et al., 2017; 27939400, Samstein et al., 2019; 30643254). Similarly, in a study of pembrolizumab in muscle invasive bladder cancer, the median TMB in responders was 12.3 Muts/Mb, versus 7.0 Muts/Mb in nonresponding patients (Necchi et al., 2018; AACR Abstract CT003). The PD_1 inhibitor nivolumab led to increased ORR, PFS, and OS for patients with a TMB of 167 missense mutations/tumor or higher (~ equivalency = 9 Muts/Mb or higher as measured by this assay) compared with those harboring lower TMB in a study of metastatic urothelial cancer (Galsky et al., 2017; ESMO Abstract 848PD).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Phase I Trial of RO5126766", "StudyPhase": "PHASE 1", "Target": "RAFs, MEK, mTOR", "Locations": "London (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT02407509", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, MEK, BRAF, EGFR", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Selumetinib and Olaparib in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, PARP", "Locations": "Texas", "NCTID": "NCT03162627", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China), Beijing (China), Chengdu City (China)", "NCTID": "NCT04589845", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)", "StudyPhase": "PHASE 1", "Target": "MDM2", "Locations": "Tokyo, Chuo_ku (Japan), Berlin (Germany), T\u00fcbingen (Germany), Leuven (Belgium), Barcelona (Spain), Ottawa (Canada), Connecticut, New York, Tennessee, Florida", "NCTID": "NCT03449381", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MDM2, PD_1", "Locations": "Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Pennsylvania, New York", "NCTID": "NCT03611868", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "ALRN_6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MDM2, MDM4", "Locations": "Texas", "NCTID": "NCT03725436", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "16354586", "FullCitation": "McIntyre A, et al. Neoplasia (2005) pmid: 16354586", "Include": "true"}, {"number": "3", "ReferenceId": "19545448", "FullCitation": "Mita H, et al. BMC Cancer (2009) pmid: 19545448", "Include": "true"}, {"number": "4", "ReferenceId": "23099803", "FullCitation": "Birkeland E, et al. Br. J. Cancer (2012) pmid: 23099803", "Include": "true"}, {"number": "5", "ReferenceId": "24874471", "FullCitation": "Chen Y, et al. PLoS ONE (2014) pmid: 24874471", "Include": "true"}, {"number": "6", "ReferenceId": "25092538", "FullCitation": "Kim PH, et al. Eur. Urol. (2015) pmid: 25092538", "Include": "true"}, {"number": "7", "ReferenceId": "28988769", "FullCitation": "Robertson AG, et al. Cell (2017) pmid: 28988769", "Include": "true"}, {"number": "8", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "9", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "10", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "11", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "12", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "13", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "14", "ReferenceId": "16337594", "FullCitation": "Sdek P, et al. Mol. Cell (2005) pmid: 16337594", "Include": "true"}, {"number": "15", "ReferenceId": "15632057", "FullCitation": "Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057", "Include": "true"}, {"number": "16", "ReferenceId": "15053880", "FullCitation": "Li M, et al. Mol. Cell (2004) pmid: 15053880", "Include": "true"}, {"number": "17", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "18", "ReferenceId": "8306343", "FullCitation": "Cordon_Cardo C, et al. Cancer Res. (1994) pmid: 8306343", "Include": "true"}, {"number": "19", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "20", "ReferenceId": "28351930", "FullCitation": "Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930", "Include": "true"}, {"number": "21", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "22", "ReferenceId": "16984978", "FullCitation": "Maluf FC, et al. Ann. Oncol. (2006) pmid: 16984978", "Include": "true"}, {"number": "23", "ReferenceId": "16006876", "FullCitation": "J. Urol. (2005) pmid: 16006876", "Include": "true"}, {"number": "24", "ReferenceId": "12908522", "FullCitation": "Tuna B, et al. Pathol. Res. Pract. (2003) pmid: 12908522", "Include": "true"}, {"number": "25", "ReferenceId": "18451213", "FullCitation": "Veerakumarasivam A, et al. Clin. Cancer Res. (2008) pmid: 18451213", "Include": "true"}, {"number": "26", "ReferenceId": "11971182", "FullCitation": "Simon R, et al. Oncogene (2002) pmid: 11971182", "Include": "true"}, {"number": "27", "ReferenceId": "17062677", "FullCitation": "L\u00f3pez_Knowles E, et al. Clin. Cancer Res. (2006) pmid: 17062677", "Include": "true"}, {"number": "28", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "29", "ReferenceId": "10931462", "FullCitation": "Jahnson S, et al. Cancer (2000) pmid: 10931462", "Include": "true"}, {"number": "30", "ReferenceId": "8064890", "FullCitation": "Lianes P, et al. J. Natl. Cancer Inst. (1994) pmid: 8064890", "Include": "true"}, {"number": "31", "ReferenceId": "10767717", "FullCitation": "Ow K, et al. J. Pathol. (2000) pmid: 10767717", "Include": "true"}, {"number": "32", "ReferenceId": "9412812", "FullCitation": "Schmitz_Dr\u00e4ger BJ, et al. Eur. Urol. (1997) pmid: 9412812", "Include": "true"}, {"number": "33", "ReferenceId": "20975744", "FullCitation": "Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744", "Include": "true"}, {"number": "34", "ReferenceId": "23165797", "FullCitation": "Ohnstad HO, et al. Cancer (2013) pmid: 23165797", "Include": "true"}, {"number": "35", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "36", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "37", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "38", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "39", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "40", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "41", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "42", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "43", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "44", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "45", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "46", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "47", "ReferenceId": "26952546", "FullCitation": "Rosenberg JE, et al. Lancet (2016) pmid: 26952546", "Include": "true"}, {"number": "48", "ReferenceId": "27939400", "FullCitation": "Balar AV, et al. Lancet (2017) pmid: 27939400", "Include": "true"}, {"number": "49", "ReferenceId": "29268948", "FullCitation": "Powles T, et al. Lancet (2018) pmid: 29268948", "Include": "true"}, {"number": "50", "ReferenceId": "29443960", "FullCitation": "Mariathasan S, et al. Nature (2018) pmid: 29443960", "Include": "true"}, {"number": "51", "ReferenceId": "30150660", "FullCitation": "Miao D, et al. Nat. Genet. (2018) pmid: 30150660", "Include": "true"}, {"number": "52", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "53", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "54", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "55", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "56", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "57", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "58", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "59", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "60", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "61", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "62", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "63", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "64", "ReferenceId": "19330029", "FullCitation": "van Haaften G, et al. Nat. Genet. (2009) pmid: 19330029", "Include": "true"}, {"number": "65", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "66", "ReferenceId": "22722829", "FullCitation": "Robinson G, et al. Nature (2012) pmid: 22722829", "Include": "true"}, {"number": "67", "ReferenceId": "23685749", "FullCitation": "Ho AS, et al. Nat. Genet. (2013) pmid: 23685749", "Include": "true"}, {"number": "68", "ReferenceId": "22722839", "FullCitation": "Grasso CS, et al. Nature (2012) pmid: 22722839", "Include": "true"}, {"number": "69", "ReferenceId": "25320243", "FullCitation": "Van der Meulen J, et al. Blood (2015) pmid: 25320243", "Include": "true"}, {"number": "70", "ReferenceId": "23792809", "FullCitation": "Wang L, et al. Nat Commun (2013) pmid: 23792809", "Include": "true"}, {"number": "71", "ReferenceId": "24491801", "FullCitation": "Kim JH, et al. Cancer Res. (2014) pmid: 24491801", "Include": "true"}, {"number": "72", "ReferenceId": "23057811", "FullCitation": "Shen Y, et al. BMC Cancer (2012) pmid: 23057811", "Include": "true"}, {"number": "73", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "74", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "75", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "76", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "77", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "78", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "79", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "80", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "81", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "82", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "83", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "84", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "85", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "86", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "87", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "88", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "89", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "90", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "91", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "92", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "93", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "94", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "95", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "96", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "97", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "98", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "99", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "100", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "101", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "102", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "103", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "104", "ReferenceId": "20890425", "FullCitation": "Lee K, et al. J. Korean Med. Sci. (2010) pmid: 20890425", "Include": "true"}, {"number": "105", "ReferenceId": "17612565", "FullCitation": "Bartoletti R, et al. J. Surg. Res. (2007) pmid: 17612565", "Include": "true"}, {"number": "106", "ReferenceId": "15590562", "FullCitation": "Eissa S, et al. IUBMB Life (2004) pmid: 15590562", "Include": "true"}, {"number": "107", "ReferenceId": "11223676", "FullCitation": "Korkolopoulou P, et al. Eur. Urol. (2001) pmid: 11223676", "Include": "true"}, {"number": "108", "ReferenceId": "11720438", "FullCitation": "Le Fr\u00e8re_Belda MA, et al. Br. J. Cancer (2001) pmid: 11720438", "Include": "true"}, {"number": "109", "ReferenceId": "23887298", "FullCitation": "Ross JS, et al. Mod. Pathol. (2014) pmid: 23887298", "Include": "true"}, {"number": "110", "ReferenceId": "16624482", "FullCitation": "Yurakh AO, et al. Eur. Urol. (2006) pmid: 16624482", "Include": "true"}, {"number": "111", "ReferenceId": "15257544", "FullCitation": "Le Fr\u00e8re_Belda MA, et al. Hum. Pathol. (2004) pmid: 15257544", "Include": "true"}, {"number": "112", "ReferenceId": "7563186", "FullCitation": "Orlow I, et al. J. Natl. Cancer Inst. (1995) pmid: 7563186", "Include": "true"}, {"number": "113", "ReferenceId": "20334706", "FullCitation": "Pollard C, et al. Expert Rev Mol Med (2010) pmid: 20334706", "Include": "true"}, {"number": "114", "ReferenceId": "18234280", "FullCitation": "Yin M, et al. Hum. Pathol. (2008) pmid: 18234280", "Include": "true"}, {"number": "115", "ReferenceId": "22422578", "FullCitation": "Rebouissou S, et al. J. Pathol. (2012) pmid: 22422578", "Include": "true"}, {"number": "116", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "117", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "118", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "119", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "120", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "121", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "122", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "123", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "124", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "125", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "126", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "127", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "128", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "129", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "130", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "131", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "132", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "133", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "134", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "135", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "136", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "137", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "138", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "139", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "140", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "141", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "142", "ReferenceId": "18254781", "FullCitation": "Mylona E, et al. APMIS (2008) pmid: 18254781", "Include": "true"}, {"number": "143", "ReferenceId": "14501713", "FullCitation": "Amira N, et al. J. Urol. (2003) pmid: 14501713", "Include": "true"}, {"number": "144", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "145", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "146", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "147", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "148", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_02 16:20:12", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "869x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BLADDER", "disease_ontology": "Bladder urothelial (transitional cell) carcinoma", "flowcell_analysis": "2000020451", "gender": "male", "pathology_diagnosis": "Urothelial carcinoma", "percent_tumor_nuclei": "20", "pipeline_version": "v3.10.1", "purity_assessment": "20.0", "specimen": "ORD_1308443_01*US1258356.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1308443_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Bladder", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "868.19", "name": "SQ_US1258356.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.54", "cds_effect": "436C>T", "depth": "737", "equivocal": "false", "functional_effect": "missense", "gene": "PARP3", "percent_reads": "54.0", "position": "chr3:51978529", "protein_effect": "H146Y", "status": "unknown", "strand": "+", "transcript": "NM_005485", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.5145", "cds_effect": "1189A>G", "depth": "793", "equivocal": "false", "functional_effect": "missense", "gene": "IDH2", "percent_reads": "51.45", "position": "chr15:90628130", "protein_effect": "M397V", "status": "unknown", "strand": "_", "transcript": "NM_002168", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.4946", "cds_effect": "188T>A", "depth": "554", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF703", "percent_reads": "49.46", "position": "chr8:37553685", "protein_effect": "L63H", "status": "unknown", "strand": "+", "transcript": "NM_025069", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.205", "cds_effect": "3354_3356delTCT", "depth": "400", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "KDM6A", "percent_reads": "20.5", "position": "chrX:44942773", "protein_effect": "L1119del", "status": "known", "strand": "+", "transcript": "NM_021140", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.5192", "cds_effect": "704C>T", "depth": "703", "equivocal": "false", "functional_effect": "missense", "gene": "PARP3", "percent_reads": "51.92", "position": "chr3:51979083", "protein_effect": "A235V", "status": "unknown", "strand": "+", "transcript": "NM_005485", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.4823", "cds_effect": "1834G>A", "depth": "790", "equivocal": "false", "functional_effect": "missense", "gene": "MLH1", "percent_reads": "48.23", "position": "chr3:37089112", "protein_effect": "V612I", "status": "unknown", "strand": "+", "transcript": "NM_000249", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"allele_fraction": "0.5482", "cds_effect": "595C>T", "depth": "695", "equivocal": "false", "functional_effect": "missense", "gene": "SMO", "percent_reads": "54.82", "position": "chr7:128845101", "protein_effect": "R199W", "status": "unknown", "strand": "+", "transcript": "NM_005631", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "16", "equivocal": "false", "gene": "KRAS", "number_of_exons": "5 of 5", "position": "chr12:25344730_25448217", "ratio": "2.64", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21968169_21994453", "ratio": "0.89", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}, {"copy_number": "15", "equivocal": "false", "gene": "MDM2", "number_of_exons": "11 of 11", "position": "chr12:69153996_69277205", "ratio": "2.48", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1258356.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}